CA2183764C - Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration - Google Patents
Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration Download PDFInfo
- Publication number
- CA2183764C CA2183764C CA002183764A CA2183764A CA2183764C CA 2183764 C CA2183764 C CA 2183764C CA 002183764 A CA002183764 A CA 002183764A CA 2183764 A CA2183764 A CA 2183764A CA 2183764 C CA2183764 C CA 2183764C
- Authority
- CA
- Canada
- Prior art keywords
- prosthesis
- diphosphonic acid
- hydroxy
- ethane
- imidazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000037099 Prosthesis Failure Diseases 0.000 title claims abstract description 33
- MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical class OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 title abstract description 19
- 241000124008 Mammalia Species 0.000 claims abstract description 18
- 230000002265 prevention Effects 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims description 31
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 238000001990 intravenous administration Methods 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 description 24
- 235000002639 sodium chloride Nutrition 0.000 description 22
- 239000000203 mixture Substances 0.000 description 19
- 229940122361 Bisphosphonate Drugs 0.000 description 15
- 150000004663 bisphosphonates Chemical class 0.000 description 13
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 210000000988 bone and bone Anatomy 0.000 description 10
- 238000000576 coating method Methods 0.000 description 10
- 239000002775 capsule Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000000454 talc Substances 0.000 description 8
- 229910052623 talc Inorganic materials 0.000 description 8
- 235000012222 talc Nutrition 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- -1 bisphosphonate compounds Chemical class 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- 241000906034 Orthops Species 0.000 description 5
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 5
- 238000011882 arthroplasty Methods 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229940014259 gelatin Drugs 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 210000001624 hip Anatomy 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- PMXAPNNYCFBALB-UHFFFAOYSA-N (1-hydroxy-1-phosphono-3-pyrrolidin-1-ylpropyl)phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CCN1CCCC1 PMXAPNNYCFBALB-UHFFFAOYSA-N 0.000 description 4
- 208000006386 Bone Resorption Diseases 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 208000010191 Osteitis Deformans Diseases 0.000 description 4
- 208000027868 Paget disease Diseases 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 4
- QWCNOXMFNSYEKF-UHFFFAOYSA-N [1-hydroxy-3-[methyl(2-phenylsulfanylethyl)amino]-1-phosphonopropyl]phosphonic acid Chemical compound OP(=O)(O)C(O)(P(O)(O)=O)CCN(C)CCSC1=CC=CC=C1 QWCNOXMFNSYEKF-UHFFFAOYSA-N 0.000 description 4
- 230000024279 bone resorption Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000004051 gastric juice Anatomy 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 208000027202 mammary Paget disease Diseases 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 229920001592 potato starch Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 229920002367 Polyisobutene Polymers 0.000 description 3
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 description 3
- NPLHDPAQRZJWHX-UHFFFAOYSA-N [5,5-bis(diethoxyphosphoryl)-1,4-dihydropyrazol-3-yl]-phenylmethanone Chemical compound N1C(P(=O)(OCC)OCC)(P(=O)(OCC)OCC)CC(C(=O)C=2C=CC=CC=2)=N1 NPLHDPAQRZJWHX-UHFFFAOYSA-N 0.000 description 3
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- 208000037147 Hypercalcaemia Diseases 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- PQBAWAQIRZIWIV-UHFFFAOYSA-N N-methylpyridinium Chemical class C[N+]1=CC=CC=C1 PQBAWAQIRZIWIV-UHFFFAOYSA-N 0.000 description 2
- 229920002398 Oppanol® B Polymers 0.000 description 2
- CZYWHNTUXNGDGR-UHFFFAOYSA-L Pamidronate disodium Chemical compound O.O.O.O.O.[Na+].[Na+].NCCC(O)(P(O)([O-])=O)P(O)([O-])=O CZYWHNTUXNGDGR-UHFFFAOYSA-L 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000013201 Stress fracture Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229960004343 alendronic acid Drugs 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000018678 bone mineralization Effects 0.000 description 2
- 230000008416 bone turnover Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229960002286 clodronic acid Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000011540 hip replacement Methods 0.000 description 2
- 230000000148 hypercalcaemia Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229940046231 pamidronate Drugs 0.000 description 2
- 229960003978 pamidronic acid Drugs 0.000 description 2
- 229920006267 polyester film Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 229960000759 risedronic acid Drugs 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960005324 tiludronic acid Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 229940038773 trisodium citrate Drugs 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IMLJLCJZQLGHJS-JEKSYDDFSA-N (4s,4ar,5s,5ar,6s,12ar)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;dihydrate Chemical compound O.O.C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O IMLJLCJZQLGHJS-JEKSYDDFSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HLNJFEXZDGURGZ-UHFFFAOYSA-M 1-methylpyridin-1-ium;iodide Chemical class [I-].C[N+]1=CC=CC=C1 HLNJFEXZDGURGZ-UHFFFAOYSA-M 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000034970 Heterotopic Ossification Diseases 0.000 description 1
- 239000013032 Hydrocarbon resin Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920002402 Oppanol® B 100 Polymers 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
- VADUXZPJGJBSLQ-UHFFFAOYSA-N [1-hydroxy-3-(1-methylpyridin-1-ium-3-yl)-1-phosphonopropyl]phosphonic acid;hydroxide Chemical compound [OH-].C[N+]1=CC=CC(CCC(O)(P(O)(O)=O)P(O)(O)=O)=C1 VADUXZPJGJBSLQ-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical compound OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 description 1
- KTGBYROLTNECAS-UHFFFAOYSA-L disodium;[2-anilino-1-[hydroxy(oxido)phosphoryl]-2-sulfanylideneethyl]-hydroxyphosphinate Chemical compound [Na+].[Na+].OP([O-])(=O)C(P(O)([O-])=O)C(=S)NC1=CC=CC=C1 KTGBYROLTNECAS-UHFFFAOYSA-L 0.000 description 1
- JFGHPLSPUGOSLV-UHFFFAOYSA-L disodium;[3-(dimethylamino)-1-hydroxy-1-[hydroxy(oxido)phosphoryl]propyl]-hydroxyphosphinate Chemical compound [Na+].[Na+].CN(C)CCC(O)(P(O)(O)=O)P([O-])([O-])=O JFGHPLSPUGOSLV-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000007941 heterotopic ossification Effects 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229920006270 hydrocarbon resin Polymers 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000001739 rebound effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940019375 tiludronate Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000011541 total hip replacement Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229940100640 transdermal system Drugs 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the use of certain methanebisphosphonic acid deriva tives (for the manufacture of a pharmaceutical compositi on) for the prevention and treatment of prosthesis loosening and prosthesis migr ation in mammals including man.
Description
W095/30421 ~ ~ ~ ~ ~ ~ 4 PGTI1895100288 Use of certain methanebisnhosohonic acid derivatives to prevent vrosthesis loosening and prosthesis ieration Arthroplasty, especially of the hip joint, is now a common procedure for the treatment of patients with osteoarthritis, rheumatoid arthritis and osteoporotic fracture.
Approximately 800 000 hip replacements are performed globally each year. This number is rising steadily, younger patients are being treated and patients are living much longer and they all expect to lead a mobile, independent life. Despite the indisputable success of this technique, often complications arise and may eventually require costly surgical revision (3 or 4 revisions being not uncommon for a single patient).
The most common complications are aseptic prosthesis loosening [see for example H.
Malchau et al., Acta Orthop. Scand. 64 (1993) 497-506; R.D. Mulroy Jr. and W.H. Harris, J. Bone Joint Surg. (Br) 72-B (1990) 757-760; M. Winter et al., Clin. Orthop.
Rel.
Research 282 (1992) 73-80] and migration of the prosthesis through bone without overt loosening [see for example B.B. Wroblewski and P.D. Siney, Clin. Orthop. Rel.
Research 285 (1992) 45-47; M. Winter et al., loc. cit.]. These complications result in considerable morbidity, such as pain and reduced mobility. They occur with both cemented and uncemented, prostheses, regardless of design, material or coating.
Previous approaches to prevent these complications have concentrated on alterations to the design of the prosthesis and the selection of different materials for its construction [see for example H. Malchau et al., loc. cit.; R.D. Mulroy Jr. and W.H. Harris, loc.
cit.; M. Winter et al., loc. cit.; B.B. Wroblewski and P.D. Siney, loc. cit.; J. Wilson-MacDonald et al., J.
Bone Joint Surg. (Br) 72-B (1990) 423-430]. Apart from some preliminary research with non-steroidal anti-inflammatory drugs [A. Ohlin and U.H. Lerner, Bone and Mineral 20 (1993) 67-78; J.H. Herman et al., J. Rheumatol. 21 (1994) 338-343], a pharmacological approach to prevent or treat the complications of arthroplasty, especially hip arthroplasty, has not been successful.
Methanebisphosphonic acid derivatives, in particular bisphosphonate compounds (_ bisphosphonates), are used clinically to inhibit excessive bone resorption in a variety of diseases such as tumour-induced osteolysis, Paget's disease and osteoporosis [H. Fleisch, Handbook of Expl. Pharmacol. 83 (1988) 441-465j. Radiolabelled bisphosphonates are also used diagnostically to identify sites of high bone turnover [B.D. Collier et al., J. Nucl.
Med. 34 (1993) 2241-2246; I. Fogelman et al., J. Nucl. Med. 34 (1993) 2247-2252].
Approximately 800 000 hip replacements are performed globally each year. This number is rising steadily, younger patients are being treated and patients are living much longer and they all expect to lead a mobile, independent life. Despite the indisputable success of this technique, often complications arise and may eventually require costly surgical revision (3 or 4 revisions being not uncommon for a single patient).
The most common complications are aseptic prosthesis loosening [see for example H.
Malchau et al., Acta Orthop. Scand. 64 (1993) 497-506; R.D. Mulroy Jr. and W.H. Harris, J. Bone Joint Surg. (Br) 72-B (1990) 757-760; M. Winter et al., Clin. Orthop.
Rel.
Research 282 (1992) 73-80] and migration of the prosthesis through bone without overt loosening [see for example B.B. Wroblewski and P.D. Siney, Clin. Orthop. Rel.
Research 285 (1992) 45-47; M. Winter et al., loc. cit.]. These complications result in considerable morbidity, such as pain and reduced mobility. They occur with both cemented and uncemented, prostheses, regardless of design, material or coating.
Previous approaches to prevent these complications have concentrated on alterations to the design of the prosthesis and the selection of different materials for its construction [see for example H. Malchau et al., loc. cit.; R.D. Mulroy Jr. and W.H. Harris, loc.
cit.; M. Winter et al., loc. cit.; B.B. Wroblewski and P.D. Siney, loc. cit.; J. Wilson-MacDonald et al., J.
Bone Joint Surg. (Br) 72-B (1990) 423-430]. Apart from some preliminary research with non-steroidal anti-inflammatory drugs [A. Ohlin and U.H. Lerner, Bone and Mineral 20 (1993) 67-78; J.H. Herman et al., J. Rheumatol. 21 (1994) 338-343], a pharmacological approach to prevent or treat the complications of arthroplasty, especially hip arthroplasty, has not been successful.
Methanebisphosphonic acid derivatives, in particular bisphosphonate compounds (_ bisphosphonates), are used clinically to inhibit excessive bone resorption in a variety of diseases such as tumour-induced osteolysis, Paget's disease and osteoporosis [H. Fleisch, Handbook of Expl. Pharmacol. 83 (1988) 441-465j. Radiolabelled bisphosphonates are also used diagnostically to identify sites of high bone turnover [B.D. Collier et al., J. Nucl.
Med. 34 (1993) 2241-2246; I. Fogelman et al., J. Nucl. Med. 34 (1993) 2247-2252].
In the orthopaedic field in general, there is a strong prejudice against using bisphosphonates. Firstly, attempts to use the commercially available bisphosphonate etidronate in the prevention of heterotopic ossification -which is another complication after arthroplasty but is very different from prosthesis loosening and prosthesis migration - proved either ineffective, or even detrimental due to a rebound effect [see for example D.E. Garland, Clin. Orthop.
Rel. Research 263 (1991) 13-29; B.J. Thomas and H.C. Amstutz, The Hip 1987, 59-69; B.J. Thomas, Orthop.
Clin. North America 23 (1992) 347-358].
Furthermore, there is increasing evidence that some bisphosphonates may inhibit bone formation and mineralization. Kanis, for example, teaches in Lancet 1984, 27-33 that bisphosphonates, as inhibitors of bone resorption, may delay the repair of microfractures by reducing the rate of remodelling. As another example, Reid et al. in Lancet 1988, 143-146 found that bisphosphonate treatment, in this particular case done with disodium pamidronate, caused a reduction in bone formation and a very low rate of bone turnover which raised the possibility of impaired microfracture repair. Adamson et al. [Lancet 342 (1993) 1459-1460) reports that pamidronate may inhibit bone mineralization in Paget's disease.
Surprisingly, it has now been found that certain methanebisphosphonic acid derivatives are useful for the cost-effective prevention or treatment of these complications of joint replacement, especially hip replacement, in mammals including man.
-2a-According to ore aspect of the present invention, there is provided use of 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid, or a pharmaceutically acceptable salt or hydrate thereof, in manufacture of a pharmaceutical composition for prevention or treatment of prosthesis loosening or prosthesis migration in a mammal.
According to another aspect of the present invention, there is provided use of 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid, or a pharmaceutically acceptable salt or hydrate thereof, for prevention or treatment of prosthesis loosening or prosthesis migration in a mammal.
According to yet another aspect of the present invention, there is provided 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid, or a pharmaceutically acceptable salt or hydrate thereof, for prevention or treatment of prosthesis loosening or prosthesis migration in a mammal.
According to still another aspect of the present invention, there is provided a pharmaceutical composition comprising 1-hydroxy-2-(imidazol-1-yl)ethane-l,l-diphosphonic acid, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier, diluent or excipient, for prevention or treatment of prosthesis loosening or prosthesis migration in a mammal.
This can be demonstrated by appropriate in vitro and in vivo tests. In particular, in vivo experiments show that the bisphosphonates according to the invention are effective in preventing prosthesis loosening in the treated animals, e.g. sheep. This is demonstrated, for example, by the following test methods: 12 adult female sheep, approx.
-2b-50 kg body weight, are randomly divided into 2 groups of 6 animals and all undergo a unilateral total hip replacement operation with implantation of a titanium prosthesis. Immediately after surgery one group of animals receives an i.v. infusion of bisphosphonate and the other group receives saline. This treatment may be subsequently repeated, for example at 4 and 8 weeks. At regular monthly intervals the hip and femoral region of each animal is subjected to both standard and quantitative digital radiography to assess changes in bone density around the prosthesis as an early indicator of prosthesis loosening.
In addition the animals are walked over a Kistler force plate to measure vertical ground reaction force from both hind limbs to determine limb functionality and, indirectly, pain. At 12 months after the operation, and 2 weeks prior to sacrifice, the animals receive a double injection, days apart, of the fluorescent bone label oxytetracycline to facilitate histomorphometric analysis. At the end of the labelling period the animals are killed and the femurs with the implants are removed for post-mortem analysis. Precision sections, cut and polished from the femurs, are subjected to microradiography to determine bone loss around the implant.
Similar sections are also analyzed by histomorphometry to assess bone resorption and formation at the tissue level. Finally sections of bone containing the implant are subjected to a mechanical "push-out" test on a materials testing machine to measure the strength of bonding between the metal implant and the surrounding bone.
A comparison of the test animals treated with a bisphosphonate according to the invention with the controls clearly shows that bisphosphonate treatment is beneficial to prevent and treat prosthesis loosening.
The invention therefore relates to the use of a methanebisphosphonic acid derivative selected from 3-amino-1-hydroxypropane-1,1-diphosphonic acid (pamidronic acid), e.g.
pamidronate;
3-(N,N-dimethylamino}-1-hydroxypropane-1,1-diphosphonic acid, e.g. dimethyl-APD;
Rel. Research 263 (1991) 13-29; B.J. Thomas and H.C. Amstutz, The Hip 1987, 59-69; B.J. Thomas, Orthop.
Clin. North America 23 (1992) 347-358].
Furthermore, there is increasing evidence that some bisphosphonates may inhibit bone formation and mineralization. Kanis, for example, teaches in Lancet 1984, 27-33 that bisphosphonates, as inhibitors of bone resorption, may delay the repair of microfractures by reducing the rate of remodelling. As another example, Reid et al. in Lancet 1988, 143-146 found that bisphosphonate treatment, in this particular case done with disodium pamidronate, caused a reduction in bone formation and a very low rate of bone turnover which raised the possibility of impaired microfracture repair. Adamson et al. [Lancet 342 (1993) 1459-1460) reports that pamidronate may inhibit bone mineralization in Paget's disease.
Surprisingly, it has now been found that certain methanebisphosphonic acid derivatives are useful for the cost-effective prevention or treatment of these complications of joint replacement, especially hip replacement, in mammals including man.
-2a-According to ore aspect of the present invention, there is provided use of 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid, or a pharmaceutically acceptable salt or hydrate thereof, in manufacture of a pharmaceutical composition for prevention or treatment of prosthesis loosening or prosthesis migration in a mammal.
According to another aspect of the present invention, there is provided use of 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid, or a pharmaceutically acceptable salt or hydrate thereof, for prevention or treatment of prosthesis loosening or prosthesis migration in a mammal.
According to yet another aspect of the present invention, there is provided 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid, or a pharmaceutically acceptable salt or hydrate thereof, for prevention or treatment of prosthesis loosening or prosthesis migration in a mammal.
According to still another aspect of the present invention, there is provided a pharmaceutical composition comprising 1-hydroxy-2-(imidazol-1-yl)ethane-l,l-diphosphonic acid, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier, diluent or excipient, for prevention or treatment of prosthesis loosening or prosthesis migration in a mammal.
This can be demonstrated by appropriate in vitro and in vivo tests. In particular, in vivo experiments show that the bisphosphonates according to the invention are effective in preventing prosthesis loosening in the treated animals, e.g. sheep. This is demonstrated, for example, by the following test methods: 12 adult female sheep, approx.
-2b-50 kg body weight, are randomly divided into 2 groups of 6 animals and all undergo a unilateral total hip replacement operation with implantation of a titanium prosthesis. Immediately after surgery one group of animals receives an i.v. infusion of bisphosphonate and the other group receives saline. This treatment may be subsequently repeated, for example at 4 and 8 weeks. At regular monthly intervals the hip and femoral region of each animal is subjected to both standard and quantitative digital radiography to assess changes in bone density around the prosthesis as an early indicator of prosthesis loosening.
In addition the animals are walked over a Kistler force plate to measure vertical ground reaction force from both hind limbs to determine limb functionality and, indirectly, pain. At 12 months after the operation, and 2 weeks prior to sacrifice, the animals receive a double injection, days apart, of the fluorescent bone label oxytetracycline to facilitate histomorphometric analysis. At the end of the labelling period the animals are killed and the femurs with the implants are removed for post-mortem analysis. Precision sections, cut and polished from the femurs, are subjected to microradiography to determine bone loss around the implant.
Similar sections are also analyzed by histomorphometry to assess bone resorption and formation at the tissue level. Finally sections of bone containing the implant are subjected to a mechanical "push-out" test on a materials testing machine to measure the strength of bonding between the metal implant and the surrounding bone.
A comparison of the test animals treated with a bisphosphonate according to the invention with the controls clearly shows that bisphosphonate treatment is beneficial to prevent and treat prosthesis loosening.
The invention therefore relates to the use of a methanebisphosphonic acid derivative selected from 3-amino-1-hydroxypropane-1,1-diphosphonic acid (pamidronic acid), e.g.
pamidronate;
3-(N,N-dimethylamino}-1-hydroxypropane-1,1-diphosphonic acid, e.g. dimethyl-APD;
4-amino-1-hydroxybutane-1,1-diphosphonic acid (alendronic acid), e.g.
alendronate;
6-amino-1-hydroxyhexane-1,1-diphosphonic acid, e.g. amino-hexyl-BP; 3-(N-methyl-N-n-pentylamino)-1-hydroxypropane-l,l-diphosphonic acid, e.g. methyl-pentyl-APD (_ BM 21.0955); 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid; 1-hydroxy-2-(3-pyridyl)ethane-1,1-diphosphonic acid (risedronic acid), e.g. risedronate, including N-methyl pyridinium salts thereof, for example N-methyl pyridinium iodides such as NE-10244 or NE-10446; 1-(4-chlorophenylthio)methane-1,1-diphosphonic acid (tiludronic acid), e.g. tiludronate; 3-[N-(2-phenylthioethyl)-N-methylamino]-1-hydroxypropane-1,1-diphosphonic acid; 1-hydroxy-3-(pyrrolidin-1-yl)propane-1,1-diphosphonic acid, e.g.
EB 1053 (Leo); I-(N-phenylaminothiocarbonyl)methane-1,1-diphosphonic acid, e.g. FR
78844 (Fujisawa); 5-benzoyl-3,4-dihydro-2H-pyrazole-3,3-diphosphonic acid tetraethyl ester, e.g. U-81581 (Upjohn); 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-l,l-diphosphonic acid, e.g. YM 529; and 1,1-dichloromethane-1,1-diphosphonic acid (clodronic acid), e.g. clodronate; or a pharmaceutically acceptable salt thereof, or any hydrate thereof, (for the manufacture of a pharmaceutical composition) for the prevention and treatment of prosthesis loosening and prosthesis migration in mammals including man.
As already mentioned above, prosthesis loosening and prosthesis migration often occurs as a complication after arthoplasty. Arthroplasty means a partial, e.g. hemi, or total ar2hroplasty of any joint, especially hip and knee, and in particular hip.
Pharmaceutically acceptable salts are preferably salts with bases, conveniently metal salts derived from groups Ia, Ib, IIa and IIb of the Periodic Table of the Elements, including alkali metal salts, e.g. potassium and especially sodium salts, or alkaline earth metal salts, preferably calcium or magnesium salts, and also ammonium salts with ammonia or organic amines.
Especially preferred pharmaceutically acceptable salts are those where one, two, three or four, in particular one or two, of the acidic hydrogens of the bisphosphonic acid are replaced by a pharmaceutically acceptable canon, in particular sodium, potassium or ammonium, in first instance sodium.
A very preferred group of pharmaceutically acceptable salts is characterized by having one acidic hydrogen and one pharmaceutically acceptable canon, especially sodium, in each ofthe phosphonic acid groups.
All the methanebisphosphonic acid derivatives mentioned above are well known from the literature. This includes their manufacture (see e.g. EP-A-513 760, pp. 13-48). For example, 3-amino-1-hydroxypropane-1,1-diphosphonic acid is prepared as described e.g.
in US patent 3,962;432 as well as in US patents 4,639,338 and 4,711,880, and 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid is prepared as described e.g. in US patent 4,939,130.
A particular embodiment of the invention is represented by the use of a methane-bisphosphonic acid derivative which is selected from 3-amino-1-hydroxypropane-1,1-diphosphonic acid, 3-(N,N-dimethylamino)-1-hydroxypropane-1,1-diphosphonic acid, 4-amino-1-hydroxybutane-1,1-diphosphonic acid, 6-amino-1-hydroxyhexane-1,1-diphos-phonic acid,3-(N-methyl-N-n-pentylamino)-1-hydroxypropane-1,1-diphosphonic acid, 1-hydroxy-2-{imidazol-1-yl)ethane-1,1-diphosphonic acid; 1-hydroxy-2-(3-pyridyl)ethane-1,1-diphosphonic acid, and N-methyl pyridinium salts thereof; 1-(4-chloro-WO 95/30421 21 ~ 3 7 6 4 -S-phenylthio)methane-1,1-diphosphonic acid, 3-[N-(2-phenylthioethyl)-N-methylamino]-1-hydroxypropane-1,1-diphosphonic acid; 1-hydroxy-3-(pyrrolidin-I-yl)propane-1,1-diphosphonic acid,l-{N-phenylaminothiocarbonyl)methane-1,1-diphosphonic acid, 5-benzoyl-3,4-dihydro-2H-pyrazole-3,3-diphosphonic acid tetraethyl ester, 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diphosphonic acid, a pharmaceutically acceptable salt thereof, and any hydrate thereof.
A preferred embodiment of the invention is represented by the use of a methane-bisphosphonic acid derivative which is selected from 3-amino-1-hydroxypropane-1,1-diphosphonic acid, 3-(N,N-dimethylamino)-1-hydroxypropane-1,1-diphosphonic acid, 4-amino-1-hydroxybutane-1,1-diphosphonic acid,6-amino-1-hydroxyhexane-1,1-diphos-phonic acid, 3-{N-methyl-N-n-pentylamino)-1-hydroxypropane-1,1-diphosphonic acid, 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid; I-hydroxy-2-(3-pyridyl)ethane-1,1-diphosphonic acid, 3-[N-(2-phenylthioethyl)-N-methylamino]-1-hydroxypropane-1,1-diphosphonic acid; 1-hydroxy-3-(pyrrolidin-I-yl)propane-1,1-diphosphonic acid, 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diphosphonic acid, a pharmaceutically acceptable salt thereof, and any hydrate thereof.
A very preferred embodiment of the invention is represented by the use of a methane-bisphosphonic acid derivative which is selected from pamidronic acid, alendronic acid, 3-(N-methyl-N-n-pentylamino)-I-hydroxypropane-1,1-diphosphonic acid, 1-hydroxy-(imidazol-1-yl)ethane-1,1-diphosphonic acid,risedronic acid and tiludronic acid, a pharmaceutically acceptable salt thereof, and any hydrate thereof.
An especially preferred embodiment of the invention is represented by the use of a methanebisphosphonic acid derivative which is selected from I-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid and 3-amino-1-hydroxypropane-1,1-diphosphonic acid,a pharmaceutically acceptable salt thereof, and any hydrate thereof.
Further the invention relates to the use of 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphos-phonic acid or a pharmaceutically acceptable salt thereof or any hydrate thereof.
Further the invention relates to the use of 3-amino-1-hydroxypropane-l, l-diphosphonic acid or a pharmaceutically acceptable salt thereof or any hydrate thereof.
The pharmaceutically useful methanebisphosphonic acid derivatives may be used in the R'O 95130421 PGT/1895/00288 form of a possible isomer or of a mixture of isomers, typically as optical isomers such as enantiomers or diastereoisomers or geometric isomers, typically cis-trans isomers. The optical isomers are obtained in the form of the pure antipodes and/or as racemates.
The pharmaceutically useful methanebisphosphonic acid derivatives can also be used in the form of their hydrates or include other solvents used for their crystallisation.
The methanebisphosphonic acid derivative is preferably used in the form of a pharmaceutical preparation that contains a therapeutically effective amount of the active ingredient optionally together with or in admixture with inorganic or organic, solid or liquid, pharmaceutically acceptable carriers which are suitable for administration.
The pharmaceutical compositions may be, for example, compositions for enteral, such as oral, rectal, aerosol inhalation or nasal administration, compositions for parenteral, such as intravenous or subcutaneous administration, or compositions for transdermal administration (e.g. passive or iontophoretic). Furthermore, direct local administration at the time of operation comes into consideration. What is meant by the latter type of administration is the coating of the exposed bone surface to which the implant is attached, with a bisphosphonate according to the invention, for example by washing the bone surface with a bisphosphonate solution. What is not meant by this type of administration is the coating of the prosthesis with bisphosphonates.
Preferably, the pharmaceutical compositions are adapted to oral or parenteral (especially intravenous or transdermal) administration before, during or after prosthesis implantation, or to local administration during prosthesis implantation. Intravenous and oral, first and foremost intravenous, adminstration is considered to be of particular importance.
The particular mode of administration and the dosage will be selected by the attending physician taking into account the particulars of the patient, especially age, weight, life style, activity level, hormonal status (e.g. post-menopausal), bone mineral density and type of prosthesis to be implanted.
The dosage of the active ingredient may depend on various factors, such as effectiveness and duration of action of the active ingredient, mode of administration, warm-blooded species, andlor sex, age, weight and individual condition of the warm-blooded animal.
-7_ Normally the dosage is such that a single dose of from 0.002 - 3.40 mg/kg, especially 0.01 - 2.40 mg/kg, is administered to a warm-blooded animal weighing approximately 75 kg. If desired, this dose may also be taken in several, optionally equal, partial doses.
"mglkg" means mg drug per kg body weight of the mammal - including man - to be treated.
The dose mentioned above - either administered as a single dose (which is preferred) or in several partial doses - may be repeated, for example once daily, once weekly, once every month, once every three months, once every six months or once a year. In other words, the pharmaceutical compositions may be administered in regimens ranging from continuous daily therapy to intermittent cyclical therapy.
Preferably, the methanebisphosphonic acid derivatives are administered in doses which are in the same order of magnitude as those used in the treatment of the diseases classically treated with methanebisphosphonic acid derivatives, such as Paget's disease, tumour-induced hypercalcaemia or osteoporosis. In other words, preferably the methanebisphosphonic acid derivatives are administered in doses which would likewise be therapeutically effective in the treatment of Paget's disease, tumour-induced hypercalcaemia or osteoporosis, i.e. preferably they are administered in doses which would likewise effectively inhibit bone resorption.
Formulations in single dose unit form contain preferably from about I % to about 90 °lo, and formulations not in single dose unit form contain preferably from about 0.1 °Jo to about 20 gb, of the active ingredient. Single dose unit forms such as capsules, tablets or dragdes contain e.g. from about 1 mg to about 500 mg of the active ingredient.
The invention further relates to the use of a composition for the manufacture of a medicament, e.g. in single dose unit form, for the prevention and treatment of prosthesis loosening and prosthesis migration in mammals including man, wherein the composition contains 0.002 - 3.40 mg/kg, especially 0.01 - 2.40 mglkg, of a methanebisphosphonic acid derivative as defined above per dosage form.
Moreover, the invention relates to the use of a methanebisphosphonic acid derivative as defined above at a dose of 0.002 - 3.40 mglkg, especially 0.01 - 2.40 mg/kg, per dosage form for the manufacture of a medicament for the prevention and treatment of prosthesis WO 9S/30421 ~' ~ ~ ~ ~ ~ PCT11895/00288 _g_ loosening and prosthesis migration in mammals including man.
Pharmaceutical preparations for enteral and parenteral administration are, for example, those in dosage unit forms, such as dragBes> tablets or capsules and also ampoules. They are prepared in a manner known per se, for example by means of conventional mixing, granulating, confectioning> dissolving or lyophilising processes. For example, pharmaceutical preparations for oral administration can be obtained by combining the active ingredient with solid carriers, where appropriate granulating a resulting mixture, and processing the mixture or granulate, if desired or necessary after the addition of suitable adjuncts, into tablets or dragBe cores.
Suitable carriers are especially fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, and also binders, such as starch pastes, using, for example, com, wheat, rice or potato starch, gelatin, tragacanth, methyl-cellulose and/or polyvinylpyrrolidone and, if desired, disintegrators, such as the above-mentioned starches, also carboxymethyl starch, crosslinked polyvinylpyrrolidone, agar or alginic acid or a salt thereof, such as sodium alginate. Adjuncts are especially flow-regulating agents and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol.
Drage cores are provided with suitable coatings that may be resistant to gastric juices, there being used, inter alb-concentrated sugar solutions that optionaliy contain gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol andlor titanium dioxide, or lacquer solutions in suitable organic solvents or solvent mixtures or, to produce coatings that are resistant to gastric juices, solutions of suitable cellulose preparations, such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate. Colouring substances or pigments may be added to the tablets or drage coatings, for example for the purpose of identification or to indicate different doses of active ingredient.
Other orally administrable pharmaceutical preparations are dry-filled capsules made of gelatin, and also soft, sealed capsules made of gelatin and a plasticiser, such as glycerol or sorbitol. The dry-filled capsules may contain the active ingredient in the form of a granulate, for example in admixture with fillers, such as lactose, binders, such as starches, and/or glidants, such as talc or magnesium stearate, and, where appropriate, stabilisers. In soft capsules the active ingredient is preferably dissolved or suspended in suitable liquids, such as fatty oils, paraffin oil or liquid polyethylene glycols, it being possible also for w0 95130421 PCTI1895I00288 stabilisers to be added.
Parenteral formulations are especially injectable fluids that are effective in various manners, such as intravenously, intramuscularly, intraperitoneally, intranasally, intradermally or subcutaneously. Such fluids are preferably isotonic aqueous solutions or suspensions which can be prepared before use, for example from lyophilised preparations which contain the active ingredient alone or together with a pharmaceutically acceptable carrier. The pharmaceutical preparations may be sterilised and/or contain adjuncts, For example preservatives, stabilisers, wetting agents and/or emulsifiers, solubilisers, salts for regulating the osmotic pressure and/or buffers.
Suitable formulations for transdermal application include an effective amount of the active ingredient with carrier. Advantageous carriers include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host.
Characteristically, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the active ingredient of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
The following Examples illustrate the invention described hereinbefore. The term "active ingredient" is to be understood as being any one of the methanebisphosphonic acid derivatives mentioned above as being useful according to the present invention.
Example 1: Capsules containing coated pellets of, for example, disodium pamidronate pentahydrate, as active ingredient:
Core pellet:
active ingredient{ground) 197.3 mg Microcrystalline cellulose 52.7 mg (Avicel~ PH 105) 250.0 mg + Inner coating:
Cellulose HP-M 603 10.0 mg Polyethylene glycol 2.0 mg ~~~1 ~3~~64 WO 95130421 PCTl1B95ID0188 Talc 8.0 mg 270.0 mg + Gastric juice-resistant outer coating:
Eudragit~ L 30 D-(solid) 90.0 mg Triethyl citrate 21.0 mg Antifoam~ AF 2.0 mg Water Talc 7.0 mg 390.0 mg A mixture of disodium pamidronate with Avicel~ PH 105 is moistened with water and kneaded, extruded and formed into spheres. The dried pellets are then successively coated in the fluidized bed with an inner coating, consisting of cellulose HP-M 603, polyethylene glycol (PEG) 8000 and talc, and the aqueous gastric juice-resistant coat, consisting of Eudragit~ L 30 D, triethyl citrate and Antifoam~ AF. The coated pellets are powdered with talc and Fzlled into capsules (capsule size 0) by means of a commercial capsule filling machine, for example Hbfliger and Karg.
Example 2: Monolith adhesive transdermal system, containing as active ingredient, for example, I-hydroxy-2-(imidazol-1-yl)-ethane-I,1-diphosphonic acid:
Composition:
polyisobutylene (PIB) 300 5.0 g (Oppanol B 1, BASF) PIB 35000 3.0 g (Oppanol B 10, BASF) P1B 1200000 -- 9.0 g (Oppanol B 100, BASF) hydrogenated hydrocarbon resin 43.0 g (Escorez 5320, Exxon) I-dodecylazacycloheptan-2-one 20.0 g (Atone, Nelson Res., Irvine/CA) active ingredient Zp~O Q
Total 100.0 g Preparation:
The above components are together dissolved in 150 g of special boiling point petroleum fraction 100-125 by rolling on a roller gear bed. The solution is applied to a polyester film (Hostaphan, Kalle) by means of a spreading device using a 300 ltm doctor blade, giving a coating of about 75 g/m2. After drying (15 minutes at 60°C), a silicone-treated polyester film (thickness 75 p,m, Iaufenberg) is applied as the peel-off film. The finished systems are punched out in sizes in the wanted form of from 5 to 30 cm2 using a punching tool.
The complete systems are sealed individually in sachets of aluminised paper.
Example 3: Vial containing 1.0 mg dry, lyophilized 1-hydroxy-2-(imidazol-1-yl}-ethane-1,1-diphosphonic acid (mixed sodium salts thereof). After dilution with 1 ml of water, a solution (concentration 1 mg/ml) for i.v. infusion is obtained.
Composition:
active ingredient (free diphosphonic acid) 1.0 mg mannitol 46.0 mg Trisodium citrate x 2 H20 ca. 3.0 mg water 1 ml water for injection 1 ml .
In 1 ml of water, the active ingredient is titrated with trisodium citrate x 2 H20 to pH 6Ø
Then, the mannitol is added and the solution is lyophilized and the lyophilisate filled into a vial.
Example 4: Ampoule containing disodium pamidronate pentahydrate dissolved in water.
The solution (concentration 3 mg/ml) is for i.v. infusion after dilution.
Composition:
active ingredient 18.73 mg 2.1.83:7 6.~
WO 95!30421 PCTlIB95/00288 ( = 15.0 mg of anhydrous active ingredient) mannitol 250 mg water for injection 5 ml .
Example 5: Tablets each containing 50 mg of 3-[N-(2-phenylthioethyl)-N-methylamino]-1-hydroxypropane-1,1-diphosphonic acid can be prepared as follows:
Composition (10,000 tablets) Active ingredient 500.0 g Lactose 500.0 g Potato starch 325.0 g Gelatin 8.0 g Talc 60.0 g Magnesium stearate 10.0 g Silicon dioxide (finely divided)20.0 g Ethanol q.s.
The active ingredient is mixed with the lactose and 292 g of potato starch, and the mixture is moistened with an ethanolic solution of the gelatin and granulated through a sieve. After the granules have dried, the remainder of the potato starch, the magnesium stearate and the silicon dioxide are admixed and the mixture compressed to give tablets each weighing 145.0 mg and containing 50.0 mg of active ingredient, which can, if desired, be provided with breaking grooves to enable the dosage to be more finely adjusted.
alendronate;
6-amino-1-hydroxyhexane-1,1-diphosphonic acid, e.g. amino-hexyl-BP; 3-(N-methyl-N-n-pentylamino)-1-hydroxypropane-l,l-diphosphonic acid, e.g. methyl-pentyl-APD (_ BM 21.0955); 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid; 1-hydroxy-2-(3-pyridyl)ethane-1,1-diphosphonic acid (risedronic acid), e.g. risedronate, including N-methyl pyridinium salts thereof, for example N-methyl pyridinium iodides such as NE-10244 or NE-10446; 1-(4-chlorophenylthio)methane-1,1-diphosphonic acid (tiludronic acid), e.g. tiludronate; 3-[N-(2-phenylthioethyl)-N-methylamino]-1-hydroxypropane-1,1-diphosphonic acid; 1-hydroxy-3-(pyrrolidin-1-yl)propane-1,1-diphosphonic acid, e.g.
EB 1053 (Leo); I-(N-phenylaminothiocarbonyl)methane-1,1-diphosphonic acid, e.g. FR
78844 (Fujisawa); 5-benzoyl-3,4-dihydro-2H-pyrazole-3,3-diphosphonic acid tetraethyl ester, e.g. U-81581 (Upjohn); 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-l,l-diphosphonic acid, e.g. YM 529; and 1,1-dichloromethane-1,1-diphosphonic acid (clodronic acid), e.g. clodronate; or a pharmaceutically acceptable salt thereof, or any hydrate thereof, (for the manufacture of a pharmaceutical composition) for the prevention and treatment of prosthesis loosening and prosthesis migration in mammals including man.
As already mentioned above, prosthesis loosening and prosthesis migration often occurs as a complication after arthoplasty. Arthroplasty means a partial, e.g. hemi, or total ar2hroplasty of any joint, especially hip and knee, and in particular hip.
Pharmaceutically acceptable salts are preferably salts with bases, conveniently metal salts derived from groups Ia, Ib, IIa and IIb of the Periodic Table of the Elements, including alkali metal salts, e.g. potassium and especially sodium salts, or alkaline earth metal salts, preferably calcium or magnesium salts, and also ammonium salts with ammonia or organic amines.
Especially preferred pharmaceutically acceptable salts are those where one, two, three or four, in particular one or two, of the acidic hydrogens of the bisphosphonic acid are replaced by a pharmaceutically acceptable canon, in particular sodium, potassium or ammonium, in first instance sodium.
A very preferred group of pharmaceutically acceptable salts is characterized by having one acidic hydrogen and one pharmaceutically acceptable canon, especially sodium, in each ofthe phosphonic acid groups.
All the methanebisphosphonic acid derivatives mentioned above are well known from the literature. This includes their manufacture (see e.g. EP-A-513 760, pp. 13-48). For example, 3-amino-1-hydroxypropane-1,1-diphosphonic acid is prepared as described e.g.
in US patent 3,962;432 as well as in US patents 4,639,338 and 4,711,880, and 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid is prepared as described e.g. in US patent 4,939,130.
A particular embodiment of the invention is represented by the use of a methane-bisphosphonic acid derivative which is selected from 3-amino-1-hydroxypropane-1,1-diphosphonic acid, 3-(N,N-dimethylamino)-1-hydroxypropane-1,1-diphosphonic acid, 4-amino-1-hydroxybutane-1,1-diphosphonic acid, 6-amino-1-hydroxyhexane-1,1-diphos-phonic acid,3-(N-methyl-N-n-pentylamino)-1-hydroxypropane-1,1-diphosphonic acid, 1-hydroxy-2-{imidazol-1-yl)ethane-1,1-diphosphonic acid; 1-hydroxy-2-(3-pyridyl)ethane-1,1-diphosphonic acid, and N-methyl pyridinium salts thereof; 1-(4-chloro-WO 95/30421 21 ~ 3 7 6 4 -S-phenylthio)methane-1,1-diphosphonic acid, 3-[N-(2-phenylthioethyl)-N-methylamino]-1-hydroxypropane-1,1-diphosphonic acid; 1-hydroxy-3-(pyrrolidin-I-yl)propane-1,1-diphosphonic acid,l-{N-phenylaminothiocarbonyl)methane-1,1-diphosphonic acid, 5-benzoyl-3,4-dihydro-2H-pyrazole-3,3-diphosphonic acid tetraethyl ester, 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diphosphonic acid, a pharmaceutically acceptable salt thereof, and any hydrate thereof.
A preferred embodiment of the invention is represented by the use of a methane-bisphosphonic acid derivative which is selected from 3-amino-1-hydroxypropane-1,1-diphosphonic acid, 3-(N,N-dimethylamino)-1-hydroxypropane-1,1-diphosphonic acid, 4-amino-1-hydroxybutane-1,1-diphosphonic acid,6-amino-1-hydroxyhexane-1,1-diphos-phonic acid, 3-{N-methyl-N-n-pentylamino)-1-hydroxypropane-1,1-diphosphonic acid, 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid; I-hydroxy-2-(3-pyridyl)ethane-1,1-diphosphonic acid, 3-[N-(2-phenylthioethyl)-N-methylamino]-1-hydroxypropane-1,1-diphosphonic acid; 1-hydroxy-3-(pyrrolidin-I-yl)propane-1,1-diphosphonic acid, 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diphosphonic acid, a pharmaceutically acceptable salt thereof, and any hydrate thereof.
A very preferred embodiment of the invention is represented by the use of a methane-bisphosphonic acid derivative which is selected from pamidronic acid, alendronic acid, 3-(N-methyl-N-n-pentylamino)-I-hydroxypropane-1,1-diphosphonic acid, 1-hydroxy-(imidazol-1-yl)ethane-1,1-diphosphonic acid,risedronic acid and tiludronic acid, a pharmaceutically acceptable salt thereof, and any hydrate thereof.
An especially preferred embodiment of the invention is represented by the use of a methanebisphosphonic acid derivative which is selected from I-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid and 3-amino-1-hydroxypropane-1,1-diphosphonic acid,a pharmaceutically acceptable salt thereof, and any hydrate thereof.
Further the invention relates to the use of 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphos-phonic acid or a pharmaceutically acceptable salt thereof or any hydrate thereof.
Further the invention relates to the use of 3-amino-1-hydroxypropane-l, l-diphosphonic acid or a pharmaceutically acceptable salt thereof or any hydrate thereof.
The pharmaceutically useful methanebisphosphonic acid derivatives may be used in the R'O 95130421 PGT/1895/00288 form of a possible isomer or of a mixture of isomers, typically as optical isomers such as enantiomers or diastereoisomers or geometric isomers, typically cis-trans isomers. The optical isomers are obtained in the form of the pure antipodes and/or as racemates.
The pharmaceutically useful methanebisphosphonic acid derivatives can also be used in the form of their hydrates or include other solvents used for their crystallisation.
The methanebisphosphonic acid derivative is preferably used in the form of a pharmaceutical preparation that contains a therapeutically effective amount of the active ingredient optionally together with or in admixture with inorganic or organic, solid or liquid, pharmaceutically acceptable carriers which are suitable for administration.
The pharmaceutical compositions may be, for example, compositions for enteral, such as oral, rectal, aerosol inhalation or nasal administration, compositions for parenteral, such as intravenous or subcutaneous administration, or compositions for transdermal administration (e.g. passive or iontophoretic). Furthermore, direct local administration at the time of operation comes into consideration. What is meant by the latter type of administration is the coating of the exposed bone surface to which the implant is attached, with a bisphosphonate according to the invention, for example by washing the bone surface with a bisphosphonate solution. What is not meant by this type of administration is the coating of the prosthesis with bisphosphonates.
Preferably, the pharmaceutical compositions are adapted to oral or parenteral (especially intravenous or transdermal) administration before, during or after prosthesis implantation, or to local administration during prosthesis implantation. Intravenous and oral, first and foremost intravenous, adminstration is considered to be of particular importance.
The particular mode of administration and the dosage will be selected by the attending physician taking into account the particulars of the patient, especially age, weight, life style, activity level, hormonal status (e.g. post-menopausal), bone mineral density and type of prosthesis to be implanted.
The dosage of the active ingredient may depend on various factors, such as effectiveness and duration of action of the active ingredient, mode of administration, warm-blooded species, andlor sex, age, weight and individual condition of the warm-blooded animal.
-7_ Normally the dosage is such that a single dose of from 0.002 - 3.40 mg/kg, especially 0.01 - 2.40 mg/kg, is administered to a warm-blooded animal weighing approximately 75 kg. If desired, this dose may also be taken in several, optionally equal, partial doses.
"mglkg" means mg drug per kg body weight of the mammal - including man - to be treated.
The dose mentioned above - either administered as a single dose (which is preferred) or in several partial doses - may be repeated, for example once daily, once weekly, once every month, once every three months, once every six months or once a year. In other words, the pharmaceutical compositions may be administered in regimens ranging from continuous daily therapy to intermittent cyclical therapy.
Preferably, the methanebisphosphonic acid derivatives are administered in doses which are in the same order of magnitude as those used in the treatment of the diseases classically treated with methanebisphosphonic acid derivatives, such as Paget's disease, tumour-induced hypercalcaemia or osteoporosis. In other words, preferably the methanebisphosphonic acid derivatives are administered in doses which would likewise be therapeutically effective in the treatment of Paget's disease, tumour-induced hypercalcaemia or osteoporosis, i.e. preferably they are administered in doses which would likewise effectively inhibit bone resorption.
Formulations in single dose unit form contain preferably from about I % to about 90 °lo, and formulations not in single dose unit form contain preferably from about 0.1 °Jo to about 20 gb, of the active ingredient. Single dose unit forms such as capsules, tablets or dragdes contain e.g. from about 1 mg to about 500 mg of the active ingredient.
The invention further relates to the use of a composition for the manufacture of a medicament, e.g. in single dose unit form, for the prevention and treatment of prosthesis loosening and prosthesis migration in mammals including man, wherein the composition contains 0.002 - 3.40 mg/kg, especially 0.01 - 2.40 mglkg, of a methanebisphosphonic acid derivative as defined above per dosage form.
Moreover, the invention relates to the use of a methanebisphosphonic acid derivative as defined above at a dose of 0.002 - 3.40 mglkg, especially 0.01 - 2.40 mg/kg, per dosage form for the manufacture of a medicament for the prevention and treatment of prosthesis WO 9S/30421 ~' ~ ~ ~ ~ ~ PCT11895/00288 _g_ loosening and prosthesis migration in mammals including man.
Pharmaceutical preparations for enteral and parenteral administration are, for example, those in dosage unit forms, such as dragBes> tablets or capsules and also ampoules. They are prepared in a manner known per se, for example by means of conventional mixing, granulating, confectioning> dissolving or lyophilising processes. For example, pharmaceutical preparations for oral administration can be obtained by combining the active ingredient with solid carriers, where appropriate granulating a resulting mixture, and processing the mixture or granulate, if desired or necessary after the addition of suitable adjuncts, into tablets or dragBe cores.
Suitable carriers are especially fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, and also binders, such as starch pastes, using, for example, com, wheat, rice or potato starch, gelatin, tragacanth, methyl-cellulose and/or polyvinylpyrrolidone and, if desired, disintegrators, such as the above-mentioned starches, also carboxymethyl starch, crosslinked polyvinylpyrrolidone, agar or alginic acid or a salt thereof, such as sodium alginate. Adjuncts are especially flow-regulating agents and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol.
Drage cores are provided with suitable coatings that may be resistant to gastric juices, there being used, inter alb-concentrated sugar solutions that optionaliy contain gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol andlor titanium dioxide, or lacquer solutions in suitable organic solvents or solvent mixtures or, to produce coatings that are resistant to gastric juices, solutions of suitable cellulose preparations, such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate. Colouring substances or pigments may be added to the tablets or drage coatings, for example for the purpose of identification or to indicate different doses of active ingredient.
Other orally administrable pharmaceutical preparations are dry-filled capsules made of gelatin, and also soft, sealed capsules made of gelatin and a plasticiser, such as glycerol or sorbitol. The dry-filled capsules may contain the active ingredient in the form of a granulate, for example in admixture with fillers, such as lactose, binders, such as starches, and/or glidants, such as talc or magnesium stearate, and, where appropriate, stabilisers. In soft capsules the active ingredient is preferably dissolved or suspended in suitable liquids, such as fatty oils, paraffin oil or liquid polyethylene glycols, it being possible also for w0 95130421 PCTI1895I00288 stabilisers to be added.
Parenteral formulations are especially injectable fluids that are effective in various manners, such as intravenously, intramuscularly, intraperitoneally, intranasally, intradermally or subcutaneously. Such fluids are preferably isotonic aqueous solutions or suspensions which can be prepared before use, for example from lyophilised preparations which contain the active ingredient alone or together with a pharmaceutically acceptable carrier. The pharmaceutical preparations may be sterilised and/or contain adjuncts, For example preservatives, stabilisers, wetting agents and/or emulsifiers, solubilisers, salts for regulating the osmotic pressure and/or buffers.
Suitable formulations for transdermal application include an effective amount of the active ingredient with carrier. Advantageous carriers include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host.
Characteristically, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the active ingredient of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
The following Examples illustrate the invention described hereinbefore. The term "active ingredient" is to be understood as being any one of the methanebisphosphonic acid derivatives mentioned above as being useful according to the present invention.
Example 1: Capsules containing coated pellets of, for example, disodium pamidronate pentahydrate, as active ingredient:
Core pellet:
active ingredient{ground) 197.3 mg Microcrystalline cellulose 52.7 mg (Avicel~ PH 105) 250.0 mg + Inner coating:
Cellulose HP-M 603 10.0 mg Polyethylene glycol 2.0 mg ~~~1 ~3~~64 WO 95130421 PCTl1B95ID0188 Talc 8.0 mg 270.0 mg + Gastric juice-resistant outer coating:
Eudragit~ L 30 D-(solid) 90.0 mg Triethyl citrate 21.0 mg Antifoam~ AF 2.0 mg Water Talc 7.0 mg 390.0 mg A mixture of disodium pamidronate with Avicel~ PH 105 is moistened with water and kneaded, extruded and formed into spheres. The dried pellets are then successively coated in the fluidized bed with an inner coating, consisting of cellulose HP-M 603, polyethylene glycol (PEG) 8000 and talc, and the aqueous gastric juice-resistant coat, consisting of Eudragit~ L 30 D, triethyl citrate and Antifoam~ AF. The coated pellets are powdered with talc and Fzlled into capsules (capsule size 0) by means of a commercial capsule filling machine, for example Hbfliger and Karg.
Example 2: Monolith adhesive transdermal system, containing as active ingredient, for example, I-hydroxy-2-(imidazol-1-yl)-ethane-I,1-diphosphonic acid:
Composition:
polyisobutylene (PIB) 300 5.0 g (Oppanol B 1, BASF) PIB 35000 3.0 g (Oppanol B 10, BASF) P1B 1200000 -- 9.0 g (Oppanol B 100, BASF) hydrogenated hydrocarbon resin 43.0 g (Escorez 5320, Exxon) I-dodecylazacycloheptan-2-one 20.0 g (Atone, Nelson Res., Irvine/CA) active ingredient Zp~O Q
Total 100.0 g Preparation:
The above components are together dissolved in 150 g of special boiling point petroleum fraction 100-125 by rolling on a roller gear bed. The solution is applied to a polyester film (Hostaphan, Kalle) by means of a spreading device using a 300 ltm doctor blade, giving a coating of about 75 g/m2. After drying (15 minutes at 60°C), a silicone-treated polyester film (thickness 75 p,m, Iaufenberg) is applied as the peel-off film. The finished systems are punched out in sizes in the wanted form of from 5 to 30 cm2 using a punching tool.
The complete systems are sealed individually in sachets of aluminised paper.
Example 3: Vial containing 1.0 mg dry, lyophilized 1-hydroxy-2-(imidazol-1-yl}-ethane-1,1-diphosphonic acid (mixed sodium salts thereof). After dilution with 1 ml of water, a solution (concentration 1 mg/ml) for i.v. infusion is obtained.
Composition:
active ingredient (free diphosphonic acid) 1.0 mg mannitol 46.0 mg Trisodium citrate x 2 H20 ca. 3.0 mg water 1 ml water for injection 1 ml .
In 1 ml of water, the active ingredient is titrated with trisodium citrate x 2 H20 to pH 6Ø
Then, the mannitol is added and the solution is lyophilized and the lyophilisate filled into a vial.
Example 4: Ampoule containing disodium pamidronate pentahydrate dissolved in water.
The solution (concentration 3 mg/ml) is for i.v. infusion after dilution.
Composition:
active ingredient 18.73 mg 2.1.83:7 6.~
WO 95!30421 PCTlIB95/00288 ( = 15.0 mg of anhydrous active ingredient) mannitol 250 mg water for injection 5 ml .
Example 5: Tablets each containing 50 mg of 3-[N-(2-phenylthioethyl)-N-methylamino]-1-hydroxypropane-1,1-diphosphonic acid can be prepared as follows:
Composition (10,000 tablets) Active ingredient 500.0 g Lactose 500.0 g Potato starch 325.0 g Gelatin 8.0 g Talc 60.0 g Magnesium stearate 10.0 g Silicon dioxide (finely divided)20.0 g Ethanol q.s.
The active ingredient is mixed with the lactose and 292 g of potato starch, and the mixture is moistened with an ethanolic solution of the gelatin and granulated through a sieve. After the granules have dried, the remainder of the potato starch, the magnesium stearate and the silicon dioxide are admixed and the mixture compressed to give tablets each weighing 145.0 mg and containing 50.0 mg of active ingredient, which can, if desired, be provided with breaking grooves to enable the dosage to be more finely adjusted.
Claims (24)
1. ~Use of 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid, or a pharmaceutically acceptable salt or hydrate thereof, in manufacture of a pharmaceutical composition for prevention or treatment of prosthesis loosening or prosthesis migration in a mammal.
2. ~Use according to claim 1, wherein the mammal is a human.
3. ~Use according to claim 1 or 2, wherein the prosthesis is a hip prosthesis.
4. ~Use according to any one of claims 1 to 3, wherein the pharmaceutical composition is in a form adapted for intravenous administration.
5. ~Use according to any one of claims 1 to 3, wherein the pharmaceutical composition is in a form adapted for transdermal administration.
6. ~Use according to any one of claims 1 to 3, wherein the pharmaceutical composition is in a form adapted for oral administration.
7. ~Use of 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid, or a pharmaceutically acceptable salt or hydrate thereof, for prevention or treatment of prosthesis loosening or prosthesis migration in a mammal.
8. ~Use according to claim 7, wherein the mammal is a human.
9. ~Use according to claim 7 or 8, wherein the prosthesis is a hip prosthesis.
10. Use according to any one of claims 7 to 9, wherein the 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid, or the salt or hydrate thereof, is in a form adapted for intravenous administration.
11. Use according to any one of claims 7 to 9, wherein the 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid, or the salt or hydrate thereof, is in a form adapted for transdermal administration.
12. Use according to any one of claims 7 to 9, wherein the 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid, or the salt or hydrate thereof, is in a form adapted for oral administration.
13. 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid, or a pharmaceutically acceptable salt or hydrate thereof, for prevention or treatment of prosthesis loosening or prosthesis migration in a mammal.
14. The 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid, or the salt or hydrate thereof, according to claim 13, wherein the mammal is a human.
15. The 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid, or the salt or hydrate thereof, according to claim 13 or 14, wherein the prosthesis is a hip prosthesis.
16. The 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid, or the salt or hydrate thereof, according to any one of claims 13 to 15 in a form adapted for intravenous administration.
17. The 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid, or the salt or hydrate thereof, according to any one of claims 13 to 15 in a form adapted for transdermal administration.
18. The 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid, or the salt or hydrate thereof, according to any one of claims 13 to 15 in a form adapted for oral administration.
19. A pharmaceutical composition comprising 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier, diluent or excipient, for prevention or treatment of prosthesis loosening or prosthesis migration in a mammal.
20. The pharmaceutical composition according to claim 19, wherein the mammal is a human.
21. The pharmaceutical composition according to claim 19 or 20, wherein the prosthesis is a hip prosthesis.
22. The pharmaceutical composition according to any one of claims 19 to 21, in a form adapted for intravenous administration.
23. The pharmaceutical composition according to any one of claims 19 to 21, in a form adapted for transdermal administration.
24. The pharmaceutical composition according to any one of claims 19 to 21, in a form adapted for oral administration.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9408775A GB9408775D0 (en) | 1994-05-04 | 1994-05-04 | Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration |
| GB9408775.6 | 1994-05-04 | ||
| PCT/IB1995/000288 WO1995030421A1 (en) | 1994-05-04 | 1995-04-24 | Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2183764A1 CA2183764A1 (en) | 1995-11-16 |
| CA2183764C true CA2183764C (en) | 2005-11-29 |
Family
ID=35520583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002183764A Expired - Fee Related CA2183764C (en) | 1994-05-04 | 1995-04-24 | Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2183764C (en) |
-
1995
- 1995-04-24 CA CA002183764A patent/CA2183764C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2183764A1 (en) | 1995-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5965547A (en) | Use of certain methanebishosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration | |
| AU2001274109B2 (en) | Method of administering bisphosphonates | |
| US20070161603A1 (en) | Method of administering bisphosphonates | |
| AU2001274109A1 (en) | Method of administering bisphosphonates | |
| WO2002043738A2 (en) | Use of bisphosphonates for pain treatment | |
| AU2002217061A1 (en) | Use of bisphosphonates for pain treatment | |
| AU775079B2 (en) | Pharmaceutical compositions and uses | |
| EP0600834A1 (en) | Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing | |
| WO2001049295A1 (en) | Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification | |
| US6255288B1 (en) | Certain methanebisphosphonic acid derivatives in fracture healing | |
| EP1591122B1 (en) | Method of administering bisphosphonates | |
| US20030212048A1 (en) | Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinase inhibitor | |
| MXPA96005327A (en) | Use of certain derivatives of acidometanisphisphonic to prevent the loosening of protesis and the emigration of proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |